Blue test tubes arranged in a line, disappearing into the background

Drug news

Jakafi (Incyte/Novartis) is FDA approved for Myelofibrosis

Read time: 1 mins

Last updated:16th Nov 2011

Published:16th Nov 2011

Source: Pharmawand

The FDA on 16 November 2011, approved Jakafi(ruxolitinib),from Incyte/Novartis, the first drug approved to specifically treat patients with the bone marrow disease Myelofibrosis. Jakafi is an inhibitor of JAK 1 and 2 (Janus Associated Kinase) that are involved in regulating blood and immunological functioning. The decision was based on two pivotal trials called COMFORT-1 and COMFORT-2.

Learning Zone

Albumin in fluid management

Explore expert-led content discussing guidelines for fluid management, clinical trial data and emerging uses of albumin in this Learning Zone.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Filing at FDA for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for approval of a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) for whom autologous stem cell transplant (ASCT) is deferred or who are ineligible for ASCT

1 mins

Drug news

Gilead Sciences signs royalty-free voluntary licenses with six generic manufacturers for lenacapavir for HIV prevention

Gilead Sciences, Inc. announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries, which are primarily low- and lower-middle income countries

1 min

Drug news

Eton Pharmaceuticals to acquire Increlex (mecasermin injection) from Ipsen S.A to treat severe IGF-1 deficiency

Eton Pharmaceuticals, Inc., announced that it has entered into an asset purchase agreement to acquire Increlex (mecasermin injection) from Ipsen S.A. The acquisition is expected to close near year-end 2024

1 min

See all news